Terry Oehler, DPM has been practicing podiatry in the Denver metro area more than 25 years. Dr Oehler recently developed Colorado Clinical Research chasing his passion for clinical research.  He has more than 27 years of experience in practicing podiatry and surgery.  He graduated from Iowa State University with a BS in Biology with emphasis in pre-med and Des Moines University with a Doctorate in Podiatric Medicine before completing a 2 year surgical residency program.

Shrenik Mehta is a Senior Principal Scientist at Genentech, where he leads efforts in biologics formulation and drug delivery technology development. With extensive expertise in sustained delivery of biologics, he has pioneered innovative technologies for ocular and subcutaneous administration. His work also encompasses the development of ultra-high concentration formulations and factors impacting subcutaneous bioavailability, significantly advancing the field of subcutaneous biologics delivery. Shrenik earned his PhD in Pharmacology from Baylor College of Medicine, providing him with a robust foundation in drug development. He is excited to share his insights on "Accomplishing Sustained Release and Long Acting Delivery" as a panelist at the PODD Conference.

TBA

TBA

TBA

Dr Elly Barry is a board-certified pediatrician and pediatric hematologist/oncologist with over 15 years of experience in drug development. Prior to joining Day One in 2021, she was Global Clinical Lead for Pediatric Oncology at Pfizer, as well as Head of Pfizer’s Pediatric Oncology Leadership Team where she oversaw more than 10 pediatric oncology clinical programs.

She has also held previous roles at Genzyme and Millenium/Takeda focused on the development of oncology therapeutics in adults. Dr Barry serves on the Industry Advisory Council for CureSearch and is a member of the ACCELERATE Platform Steering Committee. She is also a co-chair of the Children’s Oncology Group Industry Relations Council.

Dr Barry is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Tufts. She received her MD at Yale University School of Medicine and also obtained a Masters in Medical Science degree from Harvard Medical School.

Dr Kaitlin Morrison is responsible for the leadership and oversight of the LCCC clinical research infrastructure, and co-leads strategic planning driving clinical research infrastructure optimization, process improvements, recruitment/retention of employees and alignment of LCCC and UNC Healthcare system goals. Dr Morrison’s primary research interest is translation of basic and translational findings and discoveries from the bench into early phase clinical trials. She leads the office responsible for the oversight of LCCC’s clinical development program that includes investigator-initiated trials using investigational drugs/biologics provided by pharmaceutical partners, and UNC developed and/or manufactured investigational products. Her research interests focus on regulatory strategy, FDA interactions, clinical protocol development and patient education with a focus on developing clinical trials that are operationally feasible, data driven and patient friendly. She completed her understudies at University of North Carolina at Chapel Hill and PhD at Brody School of Medicine at East Carolina University.